Company news
Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(603392)"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd."Report for Q3 2026
October 26, 2026
(603392)"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
October 26, 2026
(603392)"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd."Announcement on Receipt of the Clinical Trial Approval Notice for the Company's Lyophilized Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)
October 12, 2026
(603392)"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd."Announcement on Wholly-owned Subsidiary Passing Turkish GMP Compliance Inspection
October 9, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
September 23, 2026
Notice on Convening the 1st Extraordinary General Meeting in 2026
September 7, 2026
Indicative Announcement on Change in Equity Interests of the Actual Controller and Its Persons Acting in Concert Reaching 1% Threshold
September 4, 2026
Announcement on Gratuitous Donation of Certain Shares by Actual Controller
August 25, 2026
Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
August 19, 2026
Announcement on Redemption at Maturity of Cash Management Products Purchased with Certain Idle Raised Funds and Continued Cash Management
August 12, 2026
Announcement on the Company's 9-Valent HPV Vaccine Obtaining Marketing Authorization in Thailand
August 11, 2026
Announcement on Resolutions of the 18th Meeting of the 6th Board of Directors
August 7, 2026
Announcement on Acceptance of the Clinical Trial Application for the Company's Lyophilized Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)
July 20, 2026
Announcement on Expected Loss in Semi-annual Performance for 2026
July 14, 2026
Announcement on the Resignation of a Director and General Manager and the Chairman's Assumption of the General Manager's Duties
July 3, 2026
Announcement on Progress in Using Partial Idle Raised Funds for Cash Management
June 25, 2026
Announcement on Acceptance of the Marketing Authorization Application for the Live Attenuated Varicella Vaccine
June 24, 2026
Announcement on Redemption at Maturity of Partial Idle Raised Funds Used for Cash Management
June 12, 2026
Announcement on the Submission of the WHO Prequalification Application for the Company’s Nine-valent HPV Vaccine
June 1, 2026
Announcement on the Completion of National (Excluding Hong Kong, Macao, and Taiwan) Market Access for the Company’s 9-Valent HPV Vaccine
May 29, 2026
Announcement on Directors Not Reducing Their Shareholdings and Early Termination of the Shareholding Reduction Plan
May 28, 2026
Announcement on Chairman Acting as Secretary of the Board of Directors
May 22, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 18, 2026
Announcement on "Corporate Value and Return Enhancement" Action Plan 2026
April 27, 2026
Notice on Convening the 2025 Annual General Meeting
April 20, 2026
Announcement on Approval Notice of Clinical Trial for Recombinant Trivalent Rotavirus Subunit Vaccine (Escherichia coli)
March 26, 2026
Announcement on Resignation of Secretary of Board of Directors
March 25, 2026
Announcement on Redemption at Maturity of Some Idle Raised Funds Used for Cash Management and Continuing Cash Management
March 18, 2026
Announcement on Approval for Clinical Trials of the Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)
March 16, 2026
Announcement on Plan of Shareholding Reduction by Directors through Call Auction
February 9, 2026
Announcement on Expected Loss in Performance for 2025
January 29, 2026
Announcement on the Periodic Qualification (PQ) by WHO of the Bivalent HPV Vaccine
January 26, 2026
Announcement on Completing Industrial and Commercial Change Registration and Obtaining Renewed Business License for Wholly-owned Subsidiary
January 16, 2026
Announcement on Resolutions of the 14th Meeting of the 6th Board of Directors
January 13, 2026
Announcement on Acceptance of Clinical Trial Application for Recombinant Trivalent Rotavirus Subunit Vaccine (Escherichia coli)
December 25, 2025
Announcement on Completing Industrial and Commercial Change Registration and Obtaining Renewed Business License
December 23, 2025
Announcement on Wholly-owned Subsidiary’s Inclusion in the National Immunization Program Vaccine Centralized Procurement Project
December 22, 2025
Announcement on Acceptance of Clinical Trial Application for Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)
December 17, 2025
Announcement on Implementing Cancellation of Repurchased Shares and Share Changes
December 16, 2025
Announcement on Postponing Some Investment Projects Financed by Raised Funds
December 12, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
November 28, 2025
Announcement on Resolutions of the 12th Meeting of the 6th Board of Supervisors
November 12, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
October 31, 2025
Announcement on Resolutions of the 11th Meeting of the 6th Board of Directors
October 29, 2025
Announcement on Resolutions of the 10th Meeting of the 6th Board of Directors
October 15, 2025
Announcement on the First Batch Release Certificate Obtained for 9-Valent Human Papillomavirus (HPV) Vaccine (Escherichia Coli)
August 21, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
August 20, 2025
Announcement on Expected Decrease in Semi-annual Performance for 2025
July 14, 2025
Announcement on Initiating Phase III Clinical Trial of Freeze-dried Live Attenuated Varicella-Zoster Vaccine (VZV-7D) and Completing Enrollment of the 1st Subject
June 19, 2025
Announcement on Redemption at Maturity of Some Idle Raised Funds Used for Cash Management
June 6, 2025
Decks
- Investor Presentation (April 2012)
Investor deck · 8 slides · April 2012